Peer review reports
From: Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol
Original Submission |
30 Jan 2024 |
Submitted |
Original manuscript
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
30 Apr 2024 |
Author responded |
Author comments - A.A.M. van der Veldt
|
Resubmission - Version 3 |
30 Apr 2024 |
Submitted |
Manuscript version 3
|
Publishing |
3 May 2024 |
Editorially accepted |
|
23 May 2024 |
Article published |
10.1186/s12885-024-12336-0
|
Learn about peer review